RT @Yuz6Yusof: #ACR21 #AbstrL21 Phase III RCT which stratified pts using FFS showed no superiority of Rituximab vs SOC f
Tweet Content
#ACR21 #AbstrL21 Phase III RCT which stratified pts using FFS showed no superiority of Rituximab vs SOC for remission induction of EGPA #vasculitis at Day 180 (63.5% vs 60.4%). No difference in secondary endpoints, safety or subgroup analyses @RheumNow https://t.co/AbdAvlU0Bg https://t.co/yta1CM7hrs
Links
Rituximab versus Conventional Therapeutic Strategy for Remission Induction in E…
https://bit.ly/3BZJFRS
Show on Archive Page
On
Display in Search Results
On
PDQ
Off